Sanofi
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria… Read more
Sanofi (SNYNF) - Net Assets
Latest net assets as of December 2025: $71.68 Billion USD
Based on the latest financial reports, Sanofi (SNYNF) has net assets worth $71.68 Billion USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($126.76 Billion) and total liabilities ($55.08 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $71.68 Billion |
| % of Total Assets | 56.55% |
| Annual Growth Rate | 12.18% |
| 5-Year Change | 3.84% |
| 10-Year Change | 24.18% |
| Growth Volatility | 89.33 |
Sanofi - Net Assets Trend (1999–2025)
This chart illustrates how Sanofi's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Sanofi (1999–2025)
The table below shows the annual net assets of Sanofi from 1999 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $71.68 Billion | -7.93% |
| 2024-12-31 | $77.86 Billion | +4.71% |
| 2023-12-31 | $74.35 Billion | -1.06% |
| 2022-12-31 | $75.15 Billion | +8.87% |
| 2021-12-31 | $69.03 Billion | +9.32% |
| 2020-12-31 | $63.15 Billion | +6.83% |
| 2019-12-31 | $59.11 Billion | +0.12% |
| 2018-12-31 | $59.03 Billion | +1.33% |
| 2017-12-31 | $58.26 Billion | +0.93% |
| 2016-12-31 | $57.72 Billion | -0.83% |
| 2015-12-31 | $58.21 Billion | +3.45% |
| 2014-12-31 | $56.27 Billion | -1.31% |
| 2013-12-31 | $57.01 Billion | -0.80% |
| 2012-12-31 | $57.47 Billion | +1.92% |
| 2011-12-31 | $56.39 Billion | +5.82% |
| 2010-12-31 | $53.29 Billion | +9.99% |
| 2009-12-31 | $48.45 Billion | +7.49% |
| 2008-12-31 | $45.07 Billion | +0.63% |
| 2007-12-31 | $44.79 Billion | -2.25% |
| 2006-12-31 | $45.82 Billion | -2.08% |
| 2005-12-31 | $46.79 Billion | +30.25% |
| 2004-12-31 | $35.92 Billion | +467.50% |
| 2003-12-31 | $6.33 Billion | +4.49% |
| 2002-12-31 | $6.06 Billion | +4.65% |
| 2001-12-31 | $5.79 Billion | +33.63% |
| 2000-12-31 | $4.33 Billion | +19.97% |
| 1999-12-31 | $3.61 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Sanofi's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 6685195200000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $66.85 Billion | 93.70% |
| Common Stock | $2.44 Billion | 3.42% |
| Other Comprehensive Income | $3.13 Billion | 4.39% |
| Total Equity | $71.35 Billion | 100.00% |
Sanofi Competitors by Market Cap
The table below lists competitors of Sanofi ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Agnico Eagle Mines Limited
NYSE:AEM
|
$105.00 Billion |
|
Newmont Corporation
AU:NEM
|
$105.12 Billion |
|
Boston Scientific Corp
NYSE:BSX
|
$105.26 Billion |
|
Lockheed Martin Corporation
NYSE:LMT
|
$106.03 Billion |
|
Kweichow Moutai Co Ltd
SHG:600519
|
$104.84 Billion |
|
Constellation Energy Corp
NASDAQ:CEG
|
$104.28 Billion |
|
Adobe Inc.
LSE:0R2Y
|
$104.26 Billion |
|
Adobe Systems Incorporated
NASDAQ:ADBE
|
$104.01 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Sanofi's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 77,507,000,000 to 71,349,267,000, a change of -6,157,733,000 (-7.9%).
- Net income of 7,810,074,000 contributed positively to equity growth.
- Dividend payments of 4,770,213,000 reduced retained earnings.
- Share repurchases of 5,028,116,000 reduced equity.
- New share issuances of 177,000,000 increased equity.
- Other comprehensive income decreased equity by 67,431,173,000.
- Other factors increased equity by 63,084,695,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $7.81 Billion | +10.95% |
| Dividends Paid | $4.77 Billion | -6.69% |
| Share Repurchases | $5.03 Billion | -7.05% |
| Share Issuances | $177.00 Million | +0.25% |
| Other Comprehensive Income | $-67.43 Billion | -94.51% |
| Other Changes | $63.08 Billion | +88.42% |
| Total Change | $- | -7.94% |
Book Value vs Market Value Analysis
This analysis compares Sanofi's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.78x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 21.24x to 1.78x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1999-12-31 | $4.90 | $103.98 | x |
| 2000-12-31 | $5.89 | $103.98 | x |
| 2001-12-31 | $7.88 | $103.98 | x |
| 2002-12-31 | $8.28 | $103.98 | x |
| 2003-12-31 | $8.95 | $103.98 | x |
| 2004-12-31 | $38.86 | $103.98 | x |
| 2005-12-31 | $34.61 | $103.98 | x |
| 2006-12-31 | $33.56 | $103.98 | x |
| 2007-12-31 | $32.95 | $103.98 | x |
| 2008-12-31 | $34.23 | $103.98 | x |
| 2009-12-31 | $36.86 | $103.98 | x |
| 2010-12-31 | $40.59 | $103.98 | x |
| 2011-12-31 | $42.38 | $103.98 | x |
| 2012-12-31 | $43.12 | $103.98 | x |
| 2013-12-31 | $42.48 | $103.98 | x |
| 2014-12-31 | $42.16 | $103.98 | x |
| 2015-12-31 | $43.95 | $103.98 | x |
| 2016-12-31 | $44.41 | $103.98 | x |
| 2017-12-31 | $45.85 | $103.98 | x |
| 2018-12-31 | $46.91 | $103.98 | x |
| 2019-12-31 | $46.88 | $103.98 | x |
| 2020-12-31 | $50.00 | $103.98 | x |
| 2021-12-31 | $54.60 | $103.98 | x |
| 2022-12-31 | $59.50 | $103.98 | x |
| 2023-12-31 | $58.93 | $103.98 | x |
| 2024-12-31 | $61.70 | $103.98 | x |
| 2025-12-31 | $58.46 | $103.98 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Sanofi utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 10.95%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 17.91%
- • Asset Turnover: 0.34x
- • Equity Multiplier: 1.78x
- Recent ROE (10.95%) is below the historical average (11.96%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1999 | 17.47% | 11.68% | 0.79x | 1.90x | $267.20 Million |
| 2000 | 22.89% | 16.52% | 0.76x | 1.82x | $554.60 Million |
| 2001 | 27.48% | 24.43% | 0.65x | 1.73x | $1.01 Billion |
| 2002 | 29.14% | 23.61% | 0.79x | 1.57x | $1.16 Billion |
| 2003 | 32.83% | 25.80% | 0.83x | 1.54x | $1.44 Billion |
| 2004 | -10.15% | -24.00% | 0.20x | 2.16x | $-7.16 Billion |
| 2005 | 4.84% | 7.92% | 0.33x | 1.86x | $-2.40 Billion |
| 2006 | 8.78% | 13.58% | 0.38x | 1.71x | $-554.10 Million |
| 2007 | 11.82% | 18.02% | 0.41x | 1.61x | $810.36 Million |
| 2008 | 16.02% | 24.94% | 0.40x | 1.60x | $2.70 Billion |
| 2009 | 10.93% | 17.12% | 0.38x | 1.66x | $446.20 Million |
| 2010 | 10.30% | 17.07% | 0.38x | 1.61x | $157.30 Million |
| 2011 | 10.13% | 16.24% | 0.35x | 1.78x | $71.10 Million |
| 2012 | 8.66% | 13.81% | 0.36x | 1.75x | $-766.80 Million |
| 2013 | 6.53% | 11.16% | 0.35x | 1.69x | $-1.97 Billion |
| 2014 | 7.82% | 12.87% | 0.35x | 1.74x | $-1.22 Billion |
| 2015 | 7.39% | 12.30% | 0.34x | 1.76x | $-1.52 Billion |
| 2016 | 8.18% | 13.57% | 0.33x | 1.82x | $-1.05 Billion |
| 2017 | 14.52% | 23.30% | 0.36x | 1.72x | $2.63 Billion |
| 2018 | 7.31% | 12.07% | 0.32x | 1.89x | $-1.58 Billion |
| 2019 | 4.76% | 7.46% | 0.33x | 1.91x | $-3.09 Billion |
| 2020 | 19.51% | 32.90% | 0.33x | 1.82x | $5.99 Billion |
| 2021 | 9.06% | 15.89% | 0.33x | 1.75x | $-645.10 Million |
| 2022 | 11.19% | 20.77% | 0.32x | 1.69x | $892.60 Million |
| 2023 | 7.29% | 12.98% | 0.33x | 1.71x | $-2.00 Billion |
| 2024 | 7.17% | 12.55% | 0.33x | 1.71x | $-2.19 Billion |
| 2025 | 10.95% | 17.91% | 0.34x | 1.78x | $675.15 Million |
Industry Comparison
This section compares Sanofi's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $355,057,678,100
- Average return on equity (ROE) among peers: -0.02%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Sanofi (SNYNF) | $71.68 Billion | 17.47% | 0.77x | $104.98 Billion |
| AbbVie Inc (ABBV) | $15.70 Billion | 26.61% | 0.35x | $387.90 Billion |
| Astellas Pharma Inc (ALPMF) | $1.46 Trillion | 8.50% | 0.60x | $16.93 Billion |
| Amgen Inc (AMGN) | $80.60 Million | 0.62% | 0.16x | $194.15 Billion |
| Amarin Corporation PLC (AMRN) | $24.15 Million | -158.05% | 0.75x | $303.32 Million |
| AstraZeneca PLC (AZN) | $14.91 Billion | 37.51% | 2.22x | $295.24 Billion |
| Bayer AG (BAYZF) | $20.80 Billion | 15.33% | 1.47x | $21.61 Billion |
| Biogen Inc (BIIB) | $6.43 Billion | 19.21% | 0.41x | $27.11 Billion |
| Bristol-Myers Squibb Company (BMY) | $4.75 Billion | 22.46% | 0.58x | $121.36 Billion |
| Chugai Pharmaceutical Co. Ltd (CHGCF) | $2.03 Trillion | 21.42% | 0.22x | $28.30 Billion |
| Cosmo Pharmaceuticals N.V (CMOPF) | $58.37 Million | 6.18% | 0.57x | $529.97 Million |